Cleo Diagnostics Ltd News

Cleo Diagnostics Secures US FDA Feedback for Ovarian Cancer Test

Cleo Diagnostics (ASX:COV) secured positive feedback from a pre-submission meeting with the US Food and Drug Administration for the diagnostic firm's ovarian cancer test, according to a Wednesday fili

MT NewswiresJun 26 08:15

Cleo Kicks off Long Path Towards FDA Approval for Ovarian Cancer Blood Tests

Still a relatively recent arrival to the bourse, Cleo Diagnostics (ASX:COV) has announced it’s commenced the FDA regulatory process to get into the US market.

The Market HeraldJun 26 07:55

Study Finds Cleo Diagnostics ' Blood Test Outperforms Clinical Benchmarks

Cleo Diagnostics (ASX:COV) said a study found that the company's ovarian cancer blood test outperformed current clinical benchmarks. The study confirmed that Cleo Diagnostics' blood test significantly

MT NewswiresMay 29 17:20

ASX Micro-cap Stock Rockets 50% on Ovarian Cancer Blood Test News

Cleo Diagnostics Ltd (ASX: COV) shares are catching the eye of investors on Wednesday.

The Motley FoolMay 29 11:32

Cleo Diagnostics Reports Its Ovarian Cancer Blood Tests Superior to Ultrasound

Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.

The Market HeraldMay 29 08:36

Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) has tapped Lindus Health as a key partner for its US clinical trials program, according to a Thursday filing with the Australian Securitie

MT NewswiresApr 11 09:00

CLEO Taps HcFocus for US Market Entry

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) partnered with New York-based HcFocus for its US market access campaign, according to a Tuesday filing with the Australian Securities Exch

MT NewswiresApr 2 10:49

Cleo Diagnostics Concludes Design Transfer of Ovarian Cancer Detection Test Technology

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) has concluded the design transfer activities tied to the core technology for its ovarian cancer detection test, the CXCL10 active ratio. T

MT NewswiresFeb 12 09:35

Cleo Diagnostics Confirms Efficacy of Ovarian Cancer Test From Validation Study; Shares Surge 21%

Cleo Diagnostics (ASX:COV) confirmed the efficacy of its CleoDX triage test in identifying ovarian cancer following results from a 334-patient validation study, according to a Monday report. As per th

MT NewswiresNov 6, 2023 12:43

Cleo Diagnostics Advances Development of Cancer Test Kit

Cleo Diagnostics (ASX:COV) advanced the development of its ovarian cancer test kit, according to a Monday report. The diagnostic firm has finalized the selection of biomarkers to be tested by the kit

MT NewswiresOct 9, 2023 16:31

CLEO Diagnostics Secures US Patent for Ovarian Cancer Biomarker Testing

CLEO Diagnostics (ASX:COV) secured an intellectual property protection in the US for the technology underpinning its ovarian cancer blood test. Specifically, the patent relates to methods identifying

MT NewswiresAug 22, 2023 15:53